A G-CSF functionalized scaffold for stem cells seeding: A differentiating device for cardiac purposes

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 5, 2011, Pages 1096-1108

  Spadaccio, Cristiano ^a   Rainer, Alberto ^a   Trombetta, Marcella ^a   Centola, Matteo ^a   Lusini, Mario ^a   Chello, Massimo ^a   Covino, Elvio ^a   De Marco, Federico ^b   Coccia, Raffaella ^c   Toyoda, Yoshiya ^d   Genovese, Jorge A ^a,d  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

3D scaffold; Cardiac graft; Connexin 43; Differentiation; Electrospinning; G CSF release; PLLA; Stem cells; Tissue engineering

Indexed keywords

CONNEXIN 43; GRANULOCYTE COLONY STIMULATING FACTOR; POLYESTER; POLYLACTIDE; TISSUE SCAFFOLD;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; GENETICS; HEART INFARCTION; METABOLISM; METHODOLOGY; MOUSE; MYOBLAST; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TRANSMISSION ELECTRON MICROSCOPY; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONNEXIN 43; GRANULOCYTE COLONY-STIMULATING FACTOR; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOBLASTS, SKELETAL; MYOCARDIAL INFARCTION; POLYESTERS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

MURINAE;

EID: 77958549841     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01100.x     Document Type: Article

References (81)

1. Frangogiannis NG. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res. 2004; 53: 585-95.
2. Chamberlain DA. Overview of completed sudden death trials: European experience. Cardiology. 1987; 74: 10-23.
3. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis. 1994; 37: 39-48.
4. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992; 85: I2-10.
5. Drexler H, Meyer GP, Wollert KC. Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nat Clin Pract Cardiovasc Med. 2006; 3: S65-8.
6. Kang HJ, Kim HS, Koo BK, et al Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am Heart J. 2007; 153: 237 e1-8.
7. Kang HJ, Kim HS, Zhang SY, et al Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004; 363: 751-6.
8. Kang HJ, Lee HY, Na SH, et al Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarctionversusold myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation. 2006; 114: I145-51.
9. Harada M, Qin Y, Takano H, et al G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med. 2005; 11: 305-11.
10. Sugano Y, Anzai T, Yoshikawa T, et al Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res. 2005; 65: 446-56.
11. Orlic D. Adult bone marrow stem cells regenerate myocardium in ischemic heart disease. Ann N Y Acad Sci. 2003; 996: 152-7.
12. Orlic D, Kajstura J, Chimenti S, et al Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci. 2001; 938: 221-9; discussion 9-30.
13. Orlic D, Kajstura J, Chimenti S, et al Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant. 2003; 7: 86-8.
14. Orlic D, Kajstura J, Chimenti S, et al Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701-5.
15. Orlic D, Kajstura J, Chimenti S, et al Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001; 98: 10344-9.
16. Spadaccio C, Chachques E, Chello M, et al Predifferentiated Adult Stem Cells and Matrices for Cardiac Cell Therapy. Asian Cardiovasc Thorac Ann. 2009; 17: 1-9.
17. Gnecchi M, He H, Liang OD, et al Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11: 367-8.
18. Gnecchi M, He H, Noiseux N, et al Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20: 661-9.
19. Mirotsou M, Zhang Z, Deb A, et al Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA. 2007; 104: 1643-8.
20. Dai W, Hale SL, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen Med. 2007; 2: 63-8.
21. Ohnishi S, Sumiyoshi H, Kitamura S, et al Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett. 2007; 581: 3961-6.
22. Mayer H, Bertram H, Lindenmaier W, et al Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem. 2005; 95: 827-39.
23. Li L, Zhang S, Zhang Y, et al Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep. 2009; 36: 725-31.
24. Murry CE, Soonpaa MH, Reinecke H, et al Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428: 664-8.
25. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol. 2002; 34: 241-9.
26. Chachques JC, Herreros J, Trainini J, et al Autologous human serum for cell culture avoids the implantation of cardioverter-defibrillators in cellular cardiomyoplasty. Int J Cardiol. 2004; 95: S29-33.
27. Menasche P, Hagege AA, Vilquin JT, et al Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003; 41: 1078-83.
28. He JQ, Ma Y, Lee Y, et al Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003; 93: 32-9.
29. Kuwabara M, Kakinuma Y, Katare RG, et al Granulocyte colony-stimulating factor activates Wnt signal to sustain gap junction function through recruitment of beta-catenin and cadherin. FEBS Lett. 2007; 581: 4821-30.
30. Lerner DL, Yamada KA, Schuessler RB, et al Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation. 2000; 101: 547-52.
31. van Rijen HV, Eckardt D, Degen J, et al Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. Circulation. 2004; 109: 1048-55.
32. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis. 2007; 50: 7-17.
33. Murry CE, Field LJ, Menasche P. Cell-based cardiac repair: reflections at the 10-year point. Circulation. 2005; 112: 3174-83.
34. Rubart M, Soonpaa MH, Nakajima H, et al Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation. J Clin Invest. 2004; 114: 775-83.
35. Leobon B, Garcin I, Menasche P, et al Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci USA. 2003; 100: 7808-11.
36. Hagege AA, Marolleau JP, Vilquin JT, et al Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation. 2006; 114: I108-13.
37. Aharinejad S, Marks SC Jr, Bock P, et al CSF-1 treatment promotes angiogenesis in the metaphysis of osteopetrotic (toothless, tl) rats. Bone. 1995; 16: 315-24.
38. Tojo N, Asakura E, Koyama M, et al Effects of macrophage colony-stimulating factor (M-CSF) on protease production from monocyte, macrophage and foam cellin vitro: a possible mechanism for anti-atherosclerotic effect of M-CSF. Biochim Biophys Acta. 1999; 1452: 275-84.
39. Aharinejad S, Abraham D, Paulus P, et al Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 2002; 62: 5317-24.
40. Borycki AG, Smadja F, Stanley R, et al Colony-stimulating factor 1 (CSF-1) is involved in an autocrine growth control of rat myogenic cells. Exp Cell Res. 1995; 218: 213-22.
41. Aharinejad S, Abraham D, Paulus P, et al Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation. Cardiovasc Res. 2008; 79: 395-404.
42. Giraud MN, Liechti EF, Tchantchaleishvili V, et al Myocardial injection of skeletal myoblasts impairs contractility of host cardiomyocytes. Int J Cardiol. 2010; 138: 131-7.
43. Perets A, Baruch Y, Weisbuch F, et al Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 2003; 65: 489-97.
44. Mooney DJ, Kaufmann PM, Sano K, et al Transplantation of hepatocytes using porous, biodegradable sponges. Transplant Proc. 1994; 26: 3425-6.
45. Spadaccio C, Chello M, Trombetta M, et al Drug releasing systems in cardiovascular tissue engineering. J Cell Mol Med. 2009; 13: 422-39.
46. Guneysel O, Onur OE, Denizbasi A. Effects of recombinant human granulocyte colony-stimulating factor (filgrastim) on ECG parameters in neutropenic patients: a single-centre, prospective study. Clin Drug Investig. 2009; 29: 551-5.
47. Sell SA, McClure MJ, Barnes CP, et al Electrospun polydioxanone-elastin blends: potential for bioresorbable vascular grafts. Biomed Mater. 2006; 1: 72-80.
48. Luong-Van E, Grondahl L, Chua KN, et al Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials. 2006; 27: 2042-50.
49. Kim BS, Putnam AJ, Kulik TJ, et al Optimizing seeding and culture methods to engineer smooth muscle tissue on biodegradable polymer matrices. Biotechnol Bioeng. 1998; 57: 46-54.
50. George J, Onodera J, Miyata T. Biodegradable honeycomb collagen scaffold for dermal tissue engineering. J Biomed Mater Res A. 2008; 87: 1103-11.
51. Nieponice A, Soletti L, Guan J, et al Development of a tissue-engineered vascular graft combining a biodegradable scaffold, muscle-derived stem cells and a rotational vacuum seeding technique. Biomaterials. 2008; 29: 825-33.
52. Wu X, Rabkin-Aikawa E, Guleserian KJ, et al Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2004; 287: H480-7.
53. Onodera N, Tamaki T, Okada Y, et al Identification of tissue-specific vasculogenic cells originating from murine uterus. Histochem Cell Biol. 2006; 125: 625-35.
54. He W, Yong T, Teo WE, et al Fabrication and endothelialization of collagen-blended biodegradable polymer nanofibers: potential vascular graft for blood vessel tissue engineering. Tissue Eng. 2005; 11: 1574-88.
55. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005; 23: 845-56.
56. Menasche P. Towards the second generation of skeletal myoblasts Cardiovasc Res. 2008; 79: 355-6.
57. Siepe M, Giraud MN, Liljensten E, et al Construction of skeletal myoblast-based polyurethane scaffolds for myocardial repair. Artif Organs. 2007; 31: 425-33.
58. Siepe M, Giraud MN, Pavlovic M, et al Myoblast-seeded biodegradable scaffolds to prevent post-myocardial infarction evolution toward heart failure. J Thorac Cardiovasc Surg. 2006; 132: 124-31.
59. Sarkar S, Lee GY, Wong JY, et al Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials. 2006; 27: 4775-82.
60. Xu C, Inai R, Kotaki M, et al Electrospun nanofiber fabrication as synthetic extracellular matrix and its potential for vascular tissue engineering. Tissue Eng. 2004; 10: 1160-8.
61. Stankus JJ, Soletti L, Fujimoto K, et al Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials. 2007; 28: 2738-46.
62. Soletti L, Nieponice A, Guan J, et al A seeding device for tissue engineered tubular structures. Biomaterials. 2006; 27: 4863-70.
63. Zhang Y, Cheng X, Wang J, et al Novel chitosan/collagen scaffold containing transforming growth factor-beta1 DNA for periodontal tissue engineering. Biochem Biophys Res Commun. 2006; 344: 362-9.
64. Huang ZM ZY, Kotaki M, Ramakrishna S. A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos Sci Technol. 2003; 63: 2223-53.
65. Zhang YZ, Venugopal J, Huang ZM, et al Characterization of the surface biocompatibility of the electrospun PCL-collagen nanofibers using fibroblasts. Biomacromolecules. 2005; 6: 2583-9.
66. Katti DS, Robinson KW, Ko FK, et al Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater. 2004; 70: 286-96.
67. Kim K, Luu YK, Chang C, et al Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release. 2004; 98: 47-56.
68. Zeng J, Xu X, Chen X, et al Biodegradable electrospun fibers for drug delivery. J Control Release. 2003; 92: 227-31.
69. Kenawy el R, Bowlin GL, Mansfield K, et al Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release. 2002; 81: 57-64.
70. Verreck G, Chun I, Rosenblatt J, et al Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release. 2003; 92: 349-60.
71. Luu YK, Kim K, Hsiao BS, et al Development of a nanostructured DNA delivery scaffoldviaelectrospinning of PLGA and PLA-PEG block copolymers. J Control Release. 2003; 89: 341-53.
72. Spadaccio C, Rainer A, Trombetta M, et al Poly-L-lactic acid/hydroxyapatite electrospun nanocomposites induce chondrogenic differentiation of human MSC. Ann Biomed Eng. 2009; 37: 1376-89.
73. Spadaccio C, Rainer A, Chello M, et al Drug releasing hybrid scaffold: new avenue in cardiovascular tissue engineering. Tissue Eng A. 2008; 14: 691-943.
74. Guan J, Stankus JJ, Wagner WR. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J Control Release. 2007; 120: 70-8.
75. Ziegler J, Mayr-Wohlfart U, Kessler S, et al Adsorption and release properties of growth factors from biodegradable implants. J Biomed Mater Res. 2002; 59: 422-8.
76. Hashi CK, Zhu Y, Yang GY, et al Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci USA. 2007; 104: 11915-20.
77. Ghaemi H, Behdinan K, Spence AD. In vitrotechnique in estimation of passive mechanical properties of bovine heart part I. Experimental techniques and data. Med Eng Phys. 2009; 31: 76-82.
78. Ghaemi H, Behdinan K, Spence AD. In vitrotechnique in estimation of passive mechanical properties of bovine heart part II. Constitutive relation and finite element analysis. Med Eng Phys. 2009; 31: 83-91.
79. Stroud JD, Baicu CF, Barnes MA, et al Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol. 2002; 282: H2324-35.
80. Mainil-Varlet P, Rahn B, Gogolewski S. Long-termin vivodegradation and bone reaction to various polylactides. 1. One-year results. Biomaterials. 1997; 18: 257-66.
81. Guo YH, He JG, Wu JL, et al Hepatocyte growth factor and granulocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. Cytotherapy. 2008; 10: 857-67.